Related Experiment Video
Updated: Jul 15, 2026

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
Published on: December 22, 2023
Catecholaminergic polymorphic ventricular tachycardia
Nian Liu1, Barbara Colombi, Emilia V Raytcheva-Buono
1Molecular Cardiology, Fondazione Salvatore Maugeri, Pavia, Italy.
Abstract:
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a highly lethal form of inherited arrhythmogenic disease characterized by adrenergically mediated polymorphic ventricular tachycardia. The mutations in cardiac ryanodine receptor and calsequestrin genes are responsible for the autosomal dominant and recessive variants of CPVT, respectively. The clinical presentation encompasses exercise- or emotion-induced syncopal events and a distinctive pattern of reproducible, stress-related, bidirectional ventricular tachycardia in the absence of both structural heart disease and a prolonged QT interval. The mortality rate in untreated individuals is 30-50% by age 40. Clinical evaluation by exercise stress testing and holter monitoring and genetic screening can facilitate early diagnosis. beta-adrenergic blockers are the most effective pharmacological treatment in controlling arrhythmias in CPVT patients, yet about 30% of patients still experience cardiac arrhythmias and eventually require an implantable cardioverter defibrillator.
Insights
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a dangerous inherited heart condition. Early diagnosis via genetic screening and exercise tests, along with beta-blockers, improves management but some patients still need defibrillators.
Area of Science:
- Cardiology
- Genetics
- Electrophysiology
Background:
- Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life-threatening inherited arrhythmia.
- It presents as adrenergically mediated polymorphic ventricular tachycardia, often triggered by stress.
- Mutations in RYR2 and CASQ2 genes cause dominant and recessive CPVT, respectively.
Purpose of the Study:
- To summarize the key aspects of CPVT, including its genetic basis, clinical presentation, diagnosis, and management.
- To highlight the high mortality rate in untreated CPVT patients.
- To emphasize the importance of early diagnosis and treatment strategies.
Main Methods:
- Review of clinical presentations, including exercise- or emotion-induced syncope.
- Diagnostic approaches such as exercise stress testing, Holter monitoring, and genetic screening.
- Evaluation of treatment efficacy, focusing on beta-adrenergic blockers and implantable cardioverter-defibrillators.
Main Results:
- CPVT is characterized by stress-related, bidirectional ventricular tachycardia without structural heart disease or prolonged QT.
- Untreated individuals face a 30-50% mortality rate by age 40.
- While beta-blockers are effective, approximately 30% of patients require an implantable cardioverter-defibrillator.
Conclusions:
- Early diagnosis of CPVT through clinical evaluation and genetic testing is crucial.
- Beta-adrenergic blockers are the cornerstone of pharmacological management.
- Despite treatment, a significant subset of CPVT patients necessitates advanced interventions like defibrillators due to persistent arrhythmias.
Related Concept Videos
Dysrhythmias III: Characteristics of Dysrhythmias
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Dysrhythmias II: Classification of Tachyarrhythmias
Cardiomyopathy I: Introduction and Classification
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Mechanism of Cardiac Arrhythmias
